Evidence map›Paper›PMID 37933765›Full record

ArticleCancer reports (Hoboken, N.J.)2023

Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patients.

Savannah S Shumock, William C Temple, Amanda Marinoff, Kathryn Aaronson, Erica Southworth, Simayijiang Xirenayi, Alex G Lee, Stanley G Leung, E Alejandro Sweet-Cordero, Michelle Hermiston and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Savannah S ShumockSchool of Medicine, University of California, San Francisco, California, USA.ORCID 0000-0002-6262-8210
William C TempleDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.ORCID 0000-0003-3375-2703
Amanda MarinoffDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.ORCID 0000-0001-8600-6400
Kathryn AaronsonDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.
Erica SouthworthDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.
Simayijiang XirenayiDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.
Alex G LeeDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.
Stanley G LeungDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.
E Alejandro Sweet-CorderoDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.ORCID 0000-0002-9787-9351
Michelle HermistonDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.ORCID 0000-0003-1790-2679
Christine HighamDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.ORCID 0000-0002-4618-3813
Elliot StieglitzDepartment of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.ORCID 0000-0001-7032-4623
University of California, San Francisco · US

Funding

Research Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0M
NCI NIH HHS T32 CA128583NIH HHS T32CA128583
6 · The paper itself

Abstract

backgroundThe development of tyrosine kinase inhibitors (TKIs) has significantly improved survival rates among patients with Philadelphia chromosome (Ph+) B cell acute lymphoblastic leukemia (B-ALL). Ph-like B-ALL patients lack the BCR::ABL1 translocation but share gene expression profiles with Ph+ B-ALL. The role of TKIs for Ph-like patients pre- and post-hematopoietic stem cell transplantation (HSCT) is not yet clear. CASE: Here we present five cases of pediatric, adolescent, and young adult patients who presented with Ph-like B-ALL or CML in B-ALL blast phase who were treated with personalized TKI regimens pre- and post-HSCT.

conclusionThis report describes several novel Ph-like fusions as well as combinations of TKIs with chemotherapy or immunotherapy not yet reported in the pediatric population. This case series provides real-world experience highlighting the potential application of pre- and post-HSCT use of TKIs in a subset of patients with targetable fusions.

Indexed as

Hematopoietic Stem Cell TransplantationPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentChildHumansPhiladelphia ChromosomeProtein Kinase InhibitorsYoung AdultProtein Kinase Inhibitorsacute lymphocytic leukemiachronic myeloid leukemiahematopoietic stem cell transplanttyrosine kinase inhibitor

Identifiers

PMID37933765
PMCPMC10728537
OpenAlexW4388455131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.